Business Context and Reporting Period
Company: Precision Optics Corporation, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2012 (Second Quarter of Fiscal Year 2013)
Business Overview: The Company designs and manufactures advanced optical instruments, primarily high-quality medical devices (approx. 90% of business) and military/industrial products. Recent efforts focus on commercializing next-generation 3D endoscopes and Microprecision® optical components.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2012 | Six Months Ended Dec 31, 2011 |
|---|---|---|
| Revenues | $1,062,065 | $998,523 |
| Gross Profit | $209,811 | $250,614 |
| Gross Margin | 19.8% | 25.1% |
| Operating Loss | $(710,319) | $(575,545) |
| Net Loss | $(1,264,578) | $1,673,566 (Income) |
| Cash and Equivalents (End of Period) | $1,635,422 | $786,726 |
| Total Current Liabilities | $1,160,281 | N/A |
| Long-Term Debt | $0 | $0 |
Note: The prior year net income included a one-time gain of $2,276,286 from the sale of patents.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 6.4% year-over-year for the six-month period, driven by higher unit volume sales of advanced surgical visualization systems, partially offset by lower sales of endoscopes and micro optics.
- Margin Compression: Gross margin declined from 25.1% to 19.8% due to higher consulting expenses, less favorable product mix, and nonrecurring manufacturing startup costs for new products.
- Expense Increases: Research and Development (R&D) expenses rose 24.6% to $373,952 due to higher labor and material costs for product development. Selling, General, and Administrative (SG&A) expenses increased 4.1% primarily due to consulting and insurance costs.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $145,923 at the start of the period to $1,635,422, largely due to a $2.5 million private placement of common stock and warrants in September 2012.
- Debt Repayment: The Company fully repaid its 10% Senior Secured Convertible Notes during the period, resulting in zero long-term debt.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items
- Non-Cash Provision for Liquidated Damages: The Company recorded a $629,000 non-cash expense and liability for claims related to registration rights agreements. This was settled in February 2013 via the issuance of stock and warrants rather than cash.
- Gain on Settlement of Accounts Payable: A $76,149 pre-tax gain was recorded from settling $106,149 of accounts payable for $30,000.
Outlook and Management Commentary
- Product Pipeline: Management anticipates production shipments of small endoscopes (April 2012 Order) to begin within upcoming months. New handheld 3D endoscopes and Microprecision® camera assemblies are expected to drive future revenue.
- Customer Concentration: Revenue concentration increased significantly; one customer accounted for 52% of total revenues in the six months ended Dec 31, 2012, compared to 12% in the prior year.
- Capital Needs: Management expects operating losses to continue until sales increase to breakeven levels. Proceeds from the September 2012 offering are being used for working capital and new product development.
Risks and Contingencies
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of December 31, 2012. Material weaknesses persist regarding segregation of duties (insufficient accounting staff) and inventory valuation.
- Legal Proceedings: The Company settled claims with stockholders (Special Situations, Joel Pitlor, Arnold Schumsky) regarding registration rights by issuing equity and warrants, avoiding cash outflows but increasing potential dilution.
- Tax Attributes: The September 2012 private placement may have triggered limitations on the utilization of net operating loss carryforwards under Section 382 of the Tax Reform Act of 1986.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the largest customer (52% of revenue) and the risk of order cancellations or delays.
- Internal Control Remediation: Assess the timeline and effectiveness of plans to address material weaknesses in segregation of duties and inventory valuation.
- Dilution Impact: Review the terms of the February 2013 settlements and the September 2012 private placement to understand the total number of warrants and shares outstanding.
- Product Commercialization: Confirm the status of the "April 2012 Order" for small endoscopes and the timeline for revenue recognition from new product lines.
- Cash Burn Rate: Monitor operating cash flow usage against the current cash balance of $1.6 million to determine runway before additional financing is required.